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 Transcutaneous administration has the potential to improve therapeutics 
delivery, providing an approach that is safer and more convenient than tra-
ditional alternatives, while offering the opportunity for improved therapeutic 
effi cacy through sustained/controlled drug release. To this end, a microneedle 
materials platform is demonstrated for rapid implantation of controlled-release 
polymer depots into the cutaneous tissue. Arrays of microneedles composed 
of drug-loaded poly(lactide- co -glycolide) (PLGA) microparticles or solid PLGA 
tips are prepared with a supporting and rapidly water-soluble poly(acrylic acid) 
(PAA) matrix. Upon application of microneedle patches to the skin of mice, the 
microneedles perforate the stratum corneum and epidermis. Penetration of the 
outer skin layers is followed by rapid dissolution of the PAA binder on contact 
with the interstitial fl uid of the epidermis, implanting the microparticles or solid 
polymer microneedles in the tissue, which are retained following patch removal. 
These polymer depots remain in the skin for weeks following application and 
sustain the release of encapsulated cargos for systemic delivery. To show the 
utility of this approach the ability of these composite microneedle arrays to 
deliver a subunit vaccine formulation is demonstrated. In comparison to tradi-
tional needle-based vaccination, microneedle delivery gives improved cellular 
immunity and equivalent generation of serum antibodies, suggesting the poten-
tial of this approach for vaccine delivery. However, the fl exibility of this system 
should allow for improved therapeutic delivery in a variety of diverse contexts. 
 DOI: 10.1002/adfm.201201512 
 P. C. DeMuth, Prof. D. J. Irvine
Department of Biological Engineering
Massachusetts Institute of Technology
77 Massachusetts Ave., Cambridge, MA 02139, USA
 E-mail:  djirvine@mit.edu 
 W. F. Garcia-Beltran
Program in Health Sciences and Technology
Massachusetts Institute of Technology
77 Massachusetts Ave., Cambridge, MA 02139, USA 
 M. Lim Ai-Ling
Department of Materials
Oxford University, Oxford, UK 
 Prof. P. T. Hammond
Department of Chemical Engineering
Koch Institute for Integrative Cancer Research
Institute for Soldier Nanotechnologies
Massachusetts Institute of Technology 
77 Massachusetts Ave. 
Cambridge, MA 02139, USA
E-mail: hammond@mit.edu 
 Prof. D. J. Irvine
Department of Materia
Department of Biologic
Koch Institute for Integ
Massachusetts Institut
77 Massachusetts Ave.
Cambridge, MA 02139,
 Prof. D. J. Irvine
Ragon Institute of MIT,
and Harvard, Boston, M
 Prof. D. J. Irvine
Howard Hughes Medic
4000 Jones Bridge Rd., 
Adv. Funct. Mater. 2013, 23, 161–172 1. Introduction 
 Compared to more traditional routes such 
as oral administration and hypodermic 
injection, transcutaneous drug delivery 
through chemical permeation of the skin, 
iontophoresis, ultrasound, microneedle 
treatment, or various other strategies has 
the potential to provide many practical and 
clinical advantages. [ 1 ] Relative to parenteral 
injection, transcutaneous delivery is non-
invasive, potentially allowing for rapid, 
pain-free administration either by mini-
mally trained health care providers, or 
through self-administration. [ 2 , 3 ] Transcu-
taneous delivery systems may reduce the 
generation of dangerous medical waste 
and inhibit the spread of disease known 
to occur through needle-reuse and needle-
based injury. [ 4 , 5 ] Further, dry storage of 
systems designed for topical application 
may also provide enhanced drug stability, 
enabling transport of environmentally 
sensitive biological therapeutics without 
the need for refrigeration. This is a key 
issue as the requirement of “cold chain” 
distribution increases costs and inherently 161wileyonlinelibrary.com
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world. [ 2 ] Transcutaneous therapeutic administration also has 
the potential to enhance the clinical effectiveness of treatment, 
by allowing for more effi cient delivery of drugs susceptible to 
fi rst-pass metabolism in the liver. [ 3 ] 
 Recently, microneedle arrays have been employed as an 
enabling technology for safe and convenient transcutaneous 
delivery of diverse bioactive materials, including high molec-
ular weight hydrophilic biologics, through pain-free mechanical 
disruption of the stratum corneum. For such barrier-disruption 
systems, rapid delivery of therapeutics into the skin by a brief 
application of the microneedle array is desirable, to minimize 
the potential risk of infection. This strategy has been demon-
strated by various approaches, such as the use of microneedles 
that rapidly dissolve on entry into skin with release of encap-
sulated materials over minutes to hours. [ 6– 16 ] However, while 
rapid drug release allows a brief microneedle application time, 
bolus drug delivery by microneedles, such as bolus injections, 
can lead to rapid clearance of administered drugs and a need 
for large drug doses in order for released drug to remain at 
therapeutic doses (locally and/or systemically) for a suffi cient 
temporal window to have a benefi cial effect. Sustained or 
kinetically controlled drug release is more desirable than bolus 
delivery for many therapeutics and is essential to fulfi ll the full 
potential of transcutaneous delivery for sustaining drug levels 
within a therapeutic window over time. Previous strategies for 
obtaining controlled drug release with microneedle systems 
employed intradermal injection from hollow microneedles, [ 17 ] 
or delivery from coatings on microneedle surfaces. [ 18 , 19 ] Alter-
natively, long term delivery has been achieved through encap-
sulation of drugs directly into biodegradable microneedles 
intended to remain in the skin for hours or days. [ 20 , 21 ] In each 
of these approaches, the microneedles must remain embedded 
in the skin, which raises the potential for infection in the set-
ting of long-term/continuous drug delivery over days or weeks. 
To overcome this limitation, several strategies have been devel-
oped, including the use of microneedles to generate physical 
openings in the epidermis for topically applied controlled-
release particle suspensions to diffuse into the skin, [ 22 ] rapid 
delivery of drug-loaded polymer particles into the skin using 
dissolving microneedles, [ 23 ] or fabrication of solid PLGA micro-
needles which rapidly fracture into implanted fragments upon 
skin insertion due to swelling of embedded hydrogel beads. [ 24 ] 
The success of these approaches represents a strong proof of 
principle for the potential utility of microneedle platforms pro-
viding either rapid delivery or sustained release of therapeutics 
to the skin. 
 Vaccines have been shown to vary widely in potency based on 
the duration and kinetic profi le of exposure to antigen and adju-
vant combinations. [ 25– 30 ] Recently, we demonstrated that intra-
lymph node injection of vaccines composed of soluble protein 
mixed with sustained-release adjuvant-loaded polymer particles 
could dramatically enhance the immune response to a model 
protein antigen. [ 30 ] However, intranodal injection is a more 
complex procedure than traditional vaccine administration, and 
is best suited to vaccines against cancer or more specialized set-
tings such as allergy treatment. [ 31 , 32 ] Here, we sought to deter-
mine whether control over antigen/adjuvant exposure kinetics 
could also enhance immune responses elicited by microneedle wileyonlinelibrary.com © 2013 WILEY-VCH Verlag Gvaccines applicable to widespread prophylactic vaccination. 
We developed two parallel approaches for fabrication of com-
posite dissolving microneedles combining a rapid release phase 
and sustained release phase for independently controlling the 
kinetics of antigen and adjuvant exposure during transcuta-
neous vaccination. These composite arrays were composed of 
poly(acrylic acid) (PAA) and poly (lactide- co -glycolide) (PLGA) 
in either a microparticle form or a bulk implant contained in 
the microneedle tip and intended for implantation within the 
skin upon application. PAA forms a glassy hard solid in bulk 
(Young’s modulus,  E  ≈ 4 GPa) [ 33 ] but also dissolves rapidly in 
water. Exploiting this duality, we employed bulk solid PAA as a 
supportive matrix or pedestal as well as the base of the micro-
needle array itself. When inserted into skin, near-instantaneous 
dissolution of the PAA on hydration by interstitial fl uid in skin 
provided a mechanism for rapid needle-tip disintegration or 
release and implantation in the cutaneous tissue. This approach 
enables delivery of diverse cargos that are hydrophilic or hydro-
phobic including small molecules or macromolecular drugs, 
either through encapsulation into PLGA particles or the PAA 
matrix. The selection of PLGA molecular weight or co-polymer 
ratio provides fl exibility for tuning the kinetics of sustained 
cargo release and PAA encapsulation provides the additional 
ability for bolus delivery upon dissolution in vivo. These com-
posite microneedle designs provide the ability for rapid admin-
istration leading to cutaneous implantation of controlled release 
depots for either bolus or sustained combinatorial release of 
therapeutics for various potential applications including vac-
cine delivery, as demonstrated here. 
 2. Results and Discussion 
 2.1. Fabrication of PLGA Microparticle - PAA Composite 
Microneedle Arrays 
 To create microneedle arrays capable of rapid simultaneous 
delivery of both soluble and PLGA-encapsulated cargos, we 
developed two parallel microneedle approaches intended 
to deposit either 1) PLGA microparticles or 2) solid PLGA 
implants into the superfi cial layers of the skin upon the 
aqueous dissolution of a supportive PAA matrix or pedestal. We 
hypothesized that such a platform would provide rapid admin-
istration through brief microneedle application while enabling 
combined bolus and long-term dosing of cargos released from 
cutaneously implanted PAA and PLGA depots, respectively. 
To fabricate the polymer composite microneedle structures 
needed to achieve these design goals, we employed a molding 
technique using polydimethylsiloxane (PDMS) molds. PDMS 
blocks were patterned with microscale cavities across their sur-
face by laser micromachining, yielding a negative mold. In this 
strategy, cavity shape and the resulting microneedle geometry 
are easily controllable through variation of the laser micro-abla-
tion process. [ 19 ] We selected molds containing conical cavities, 
approximately 700  μ m in height and 250  μ m in width at the 
base. Microneedles of this size and shape have been shown 
to effectively penetrate the murine stratum corneum for cuta-
neous materials delivery [ 19 ] and are also appropriate for delivery mbH & Co. KGaA, Weinheim Adv. Funct. Mater. 2013, 23, 161–172
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 Figure  1 .  Schematic view of composite microparticle and bulk PLGA tip 
microneedle array fabrication. PDMS molds were fi rst fi lled with PLGA 
microparticles through centrifugation (1). PLGA microparticles were then 
either dried in mold cavities (2a) or fused at high temperature to create a 
solid tip (2b). Concentrated aq. PAA solution was then centrifuged onto 
the fi lled molds to create a supportive matrix (3a) or pedestal (3b) for 
rapid dissolution in vivo. After drying microneedles were removed from 
PDMS molds (4a, 4b). in humans. To begin the microneedle fabrication process, 
PLGA microparticles (1580  ± 95 nm in diameter, –26  ± 2 mV 
zeta potential) formed through double-emulsion-solvent-evap-
oration were applied to the surface of the mold in aqueous 
suspension and compacted into the mold cavities through cen-
trifugation ( Figure  1 , step 1). Excess microparticles were then 
removed from the PDMS surface and the microparticle-loaded 
mold was allowed to dry (Figure  1 , step 2a). To form dissolving 
microneedles carrying dispersible PLGA microparticles, we 
next added a concentrated aqueous solution of PAA (35 wt%) 
to the mold surface and infi ltrated the PAA solution into the 
packed PLGA particle bed via centrifugation (Figure  1 , step 3a). 
The loaded molds were then dried at 25  ° C for 48 h before des-
iccation under vacuum to obtain solid PLGA-PAA microparticle © 2013 WILEY-VCH Verlag GmAdv. Funct. Mater. 2013, 23, 161–172matrices. The dry composite microneedles were fi nally removed 
from the PDMS mold for characterization or stored under 
vacuum at 25  ° C until use (Figure  1 , step 4a). 
 To characterize the internal structure of microneedles cre-
ated in this way, we performed the described fabrication steps 
using PLGA microparticles loaded with distinct lipophilic 
fl uorescent tracers to serve as a model drug cargos: either 
1,1 ′ -dilinoleyl-3,3,3 ′ ,3 ′ -tetramethylindocarbocyanine (DiI) or 
1,1-dinoleyl-3,3,3 ′ ,3 ′ -tetramethylindoc dicarbocyanine (DiD). 
Localization of the PAA matrix within the microneedle array 
was tracked through encapsulation of Alexafl uor-488 (AF488) as 
a hydrophilic fl uorescent tracer in the PAA matrix. The AF488 
dye also served as a model for potential hydrophilic therapeutic 
compounds that could be encapsulated for bolus cutaneous 
delivery upon dissolution of the PAA matrix in vivo. Confocal 
imaging of microneedles fabricated using DiD-loaded PLGA 
microparticles together with AF488-loaded PAA showed uni-
form microneedle formation with DiD fl uorescence localized 
in the microneedle tip, and AF488 fl uorescence throughout 
the needle length ( Figure  2 a). This indicates the successful 
deposition of PLGA microparticles to the microneedle tip, and 
the effective formation of an encapsulating, supportive PAA 
matrix surrounding the microparticles and forming the base 
of the microneedle array itself. Further, confocal analysis dem-
onstrated the fl exibility of this approach through the similar 
successful fabrication of microneedles bearing multiple micro-
particle populations encapsulating either DiD or DiI in two dif-
ferent microparticle populations comprised of PLGA with high 
vs. low molecular weight (to obtain two distinct kinetics of drug 
release; see Figure S1a, Supporting Information). SEM imaging 
demonstrated the fi delity of the fi nal composite microneedles to 
the mold cavity architecture (Figure  2 b). Additional imaging of 
the internal structure of needles intentionally broken after fab-
rication also confi rmed the confocal imaging results, showing 
the presence of nodules of discrete PLGA microparticles sur-
rounded by PAA matrix (Figure  2 c). 
 2.2. Fabrication of Solid PLGA-PAA Composite Microneedle Arrays 
 A similar fabrication approach was developed for the genera-
tion of microneedles capable of implanting solid PLGA tips 
directly into skin. As previously described, PLGA microparticles 
were fi rst deposited into the cavities of a PDMS mold (Figure  1 , 
step 1). After drying, the microparticle-loaded PDMS molds 
were incubated at 140 ° C for 40 min under vacuum to fuse the 
embedded PLGA particles. The molds were then allowed to cool, 
solidifying the PLGA into solid cones at the tips of each mold 
cavity (Figure  1 , step 2b). As before, concentrated PAA was then 
added and infi ltrated into the PDMS molds through centrifuga-
tion, before drying and fi nally removal of the completed arrays 
(Figure  1 , steps 3b and 4b). Confocal imaging of DiD-loaded 
PLGA together with AF488-loaded PAA showed the internal 
composite structure of the resulting microneedle arrays. In this 
case fl uorescent signal from encapsulated DiD-loaded PLGA 
was localized to the tip of the microneedles, while AF488-
PAA was only seen forming the base of the microneedle array 
( Figure  3 a), consistent with the melted microparticles forming 
a continuous PLGA matrix in the microneedle tip, supported by 163wileyonlinelibrary.combH & Co. KGaA, Weinheim
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 Figure  3 .  a) Confocal microscopy images of PLGA-PAA composite microneedles fabricated with a PAA base and DiD-loaded solid PLGA tip (scale bar 
200  μ m). Confocal microscopy images of microneedles fabricated with varying amounts of DiD-loaded PLGA microparticles as indicated giving a range 
of PLGA tip sizes (b) and PAA pedestal heights (c). 
 Figure  2 .  a) Confocal microscopy images of PLGA-PAA composite microneedles fabricated to encapsulate DiD-loaded PLGA microparticles (MP) 
(right, scale bar 200  μ m). SEM images of b) resulting microparticle-encapsulating microneedle array (scale bar 200  μ m) and c) high magnifi cation 
image of the composite needle interior of a fractured microneedle (scale bar 10  μ m). 
Adv. Funct. Mater. 2013, 23, 161–172
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two distinct PLGA microparticle populations were sequentially 
added and melted in sequence yielded a layered microneedle 
structure in which the DiD-loaded PLGA added fi rst formed the 
needle tip, while the remainder of the needle was composed 
of the second DiI-loaded PLGA layer, and fi nally the AF488-
loaded PAA pedestal (Figure S1b, Supporting Information). 
Fine control over the size of the PLGA “warheads” (and there-
fore of encapsulated drug cargos) was readily achieved through 
simple variation of the mass of PLGA microparticles added to 
the mold. Confocal imaging analysis of microneedles fabricated 
using varying amounts of PLGA microparticles showed the for-
mation of PLGA tips of increasing height and correspondingly 
shorter PAA pedestals as the mass of added PLGA particles was 
increased (Figure  3 b,c). Control over PLGA tip size and PAA 
pedestal height is potentially an important parameter not only 
for controlling cargo dosage, but also for effi ciency of delivery 
upon insertion to the skin. © 2013 WILEY-VCH Verlag Gm
 Figure  4 .  a) Schematic of PAA/microparticle composite microneedle disso
recovered following 5 s exposure of composite microneedles to PBS solutio
tion and confocal microscopy image of DiD-loaded PLGA microneedle tips
bar 200  μ m). 
Adv. Funct. Mater. 2013, 23, 161–172 2.3. In Vitro Testing of Composite Microneedle Delivery 
 To test our hypothesis that PLGA-PAA composite microneedles 
should be able to rapidly release either PLGA microparticles or 
solid PLGA tips upon exposure to interstitial fl uids in the skin, 
we exposed composite microneedles to phosphate buffered 
saline (PBS) in vitro for short periods of time to observe the 
kinetics of PAA dissolution. When PAA microneedles encapsu-
lating DiD-loaded PLGA particles were submerged in PBS, PAA 
dissolution was nearly instantaneous. After 5 s, the remaining 
microneedle array backing was recovered and the released 
microparticles were collected through centrifugation of the PBS 
solution for confocal imaging. The recovered particles were 
identical to those initially used for microneedle fabrication with 
no particle aggregation observed ( Figure  4 a). PAA microneedles 
encapsulating DiD-loaded bulk PLGA tip implants were simi-
larly exposed to PBS and exhibited equally rapid separation from 
the residual PAA base after only 5 s. After centrifugation 165wileyonlinelibrary.combH & Co. KGaA, Weinheim
lution and confocal microscopy image of DiD-loaded PLGA microparticles 
n (scale bar 10  μ m). b) Schematic of PLGA solid tip microneedle dissolu-
 recovered following 5 s exposure of solid tip microneedles to PBS (scale 
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 Figure  5 .  a) Microneedle delivery scheme: 1) Microneedle (MN) arrays are applied briefl y to penetrate skin. 2) Cutaneous microneedle penetration 
exposes needles to interstitial fl uid resulting in rapid dissolution of the supportive PAA matrix and microneedle disintegration. 3) Following microneedle 
base removal, microparticles are left behind at penetration sites where soluble PAA-encapsulated cargoes are rapidly delivered to the surrounding tissue. 
4) Microparticle deposition into the skin establishes a depot for sustained delivery of PLGA encapsulated cargoes over time. b) Confocal microscopy 
image of DiD-microparticle-loaded microneedles before application (left) and following a 5 min application to murine skin (right, scale bar 200  μ m). 
c) Optical microscopy image of microneedle-treated skin showing penetration sites stained using trypan blue (scale bar 500  μ m). d) Confocal micro-
scopy image of treated skin, showing deposition of DiD-loaded PLGA microparticles together with soluble AF488-loaded PAA at needle penetration 
sites directly following microneedle application for 5 min (scale bar 100  μ m, penetration sites outlined). e) Reconstructed confocal  x - y / x - z / y - z images 
depicting the microneedle application site showing deposition of microparticle-cargos within the cutaneous tissue (scale bar 100  μ m). for collection, confocal imaging of the released PLGA tips 
showed retention of overall tip morphology (Figure  4 b). 
Together these results suggested that the composite PLGA-PAA 
microneedle designs we had fabricated should be capable of 
rapidly depositing their PLGA payload upon dissolution of the 
supportive PAA matrix or pedestal in skin interstitial fl uids. 
 2.4. In Vivo Composite Microneedle Delivery 
 Given the rapid in vitro release of both PLGA particles and solid 
PLGA tips from PLGA-PAA microneedles, we next sought to 
test the delivery capabilities of these composite designs in vivo. 
We hypothesized that composite microneedles encapsulating 
PLGA particles should have suffi cient strength to penetrate 
the skin upon application ( Figure  5 a, step 1) before exposure 
to fl uid in the cutaneous tissue would cause rapid dissolution 
of the PAA supportive matrix (Figure  5 a, step 2). This would 
then lead to disintegration of the microneedle itself, releasing 
and implanting the encapsulated microparticles into the epi-
dermis (Figure  5 a, step 3). Then, after the residual microneedle 
backing was removed, implanted microparticles would remain 
as cutaneous depots for hydrolytic degradation and sustained 
release of their encapsulated cargos in situ (Figure  5 a, step 4). 
We fi rst tested AF488-PAA microneedles encapsulating DiD-
loaded PLGA microparticles. To determine the effi ciency and 
timescale of PAA dissolution and PLGA microparticle release, 
we applied microneedles to the dorsal ear skin of anesthetized 
C57Bl/6 mice. Following application to the skin, we performed 
confocal imaging on the post-application microneedle arrays 6 wileyonlinelibrary.com © 2013 WILEY-VCH Verlag Gto observe residual microneedle morphologies. Similar to the 
in vitro results, microneedle application to murine skin in 
vivo for 5 min was suffi cient to produce nearly complete loss 
of both DiD-PLGA signal and AF488-PAA signal in the micro-
needle shaft, indicating rapid dissolution and disintegration 
of the composite microneedle matrix (Figure  5 b). We stained 
the skin surface over the microneedle application site with 
trypan blue to visualize areas of stratum corneum disruption, 
and found uniform and consistent penetration of the com-
posite microneedle arrays to the viable epidermis (Figure  5 c). 
Confocal imaging analysis of dissected skin samples immedi-
ately following microneedle application indicated the presence 
of cutaneous microparticle depots at the sites of microneedle 
penetration, with colocalization of fl uorescent signal from DiD-
loaded PLGA microparticles and AF488 from the dissolved PAA 
matrix (Figure  5 d). Using 3D rendering of confocal z-stacks, 
these depots were observed to extend 300–400  μ m below the 
skin surface, consistent with the proposed paradigm for intact 
microneedle insertion, followed by PAA dissolution and micro-
needle disintegration, leaving depots of implanted material fol-
lowing removal of the microneedle backing (Figure  5 e). Notably, 
we did not observe any short- or long-term local toxicity due to 
PAA exposure on the skin of treated animals, despite the rela-
tively large chain length of the polymers used. This is likely due 
to the small amount of PAA (≤150  μ g) introduced into the skin 
tissue through microneedle application, as well as the known 
low toxicity of PAA in commercial topical indications such as in 
detergents, cosmetics, or pharmaceutical use. [ 34 ] 
 We hypothesized a similar mechanism for delivery in the 
case of composite microneedles bearing bulk PLGA tips. As mbH & Co. KGaA, Weinheim Adv. Funct. Mater. 2013, 23, 161–172
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tively insert into the outer layers of the skin before dissolution 
of the PAA pedestal by interstitial fl uid, causing release and 
implantation of the PLGA tip for degradation and release of 
encapsulated cargos over time (Figure S2a, Supporting Infor-
mation). Using AF488-PAA microneedles bearing DiD-loaded 
solid PLGA tips, we performed a similar set of tests to assay 
composite microneedle performance in vivo. As in the case of 
microparticle-loaded microneedles, application of composite 
microneedles bearing bulk PLGA tip implants for only 5 min 
to murine skin gave complete loss of DiD-PLGA signal as well 
as AF488-PAA signal from the patch backing, indicating PAA 
dissolution and needle tip separation (Figure S2b, Supporting 
Information). Trypan blue staining also confi rmed that bulk 
PLGA tipped microneedles were able to penetrate skin consist-
ently (Figure S2c, Supporting Information) following applica-
tion for 5 min. Finally, confocal imaging of dissected skin fol-
lowing microneedle array application showed implantation of 
the PLGA microneedle tips following removal of the residual 
microneedle array base (Figure S2d, Supporting Informa-
tion). As in the case of microparticle delivery, these bulk PLGA 
implants were observed 300–400  μ m below the skin surface at 
the sites of microneedle penetration, together with fl uorescent 
signal from the dissolved PAA pedestal (Figure S2e, Supporting 
Information). 
 2.5. Formation and Retention of Cutaneous Particle Depots 
for Sustained Cargo Release 
 We next sought to determine the fate of soluble PAA-loaded 
cargo and microparticle-loaded model drugs following depo-
sition into the skin by composite microneedle application. As 
previously described, microneedles encapsulating DiD-loaded 
PLGA microparticles in an AF488-loaded PAA microneedle 
matrix were applied to the fl ank skin of C57Bl/6 mice for 
5 min. Following treatment, individual animals were euthanized 
at various time points, and after dissection of the treatment site, 
confocal imaging and histological sectioning were performed to 
detect the presence of microparticle depots in the skin. Histo-
logical sectioning of tissue collected 24 h after treatment showed 
distinct cutaneous depots of microparticles extending several 
hundred micrometers below the skin surface, colocalizing with 
signal from PAA-encapsulated AF488 ( Figure  6 a). Similarly, 
confocal imaging of treated skin 24 h after administration indi-
cated the retention of cutaneous microparticle deposits at the 
sites of microneedle insertion (Figure  6 b). Consistent with the 
histological evidence, optical sectioning analysis of confocal 
data indicated the colocalization of DiD-labeled particle depots 
extending 300-400  μ m beneath the skin surface. High magnifi -
cation imaging of the depot site showed individual particles dis-
persed within the cutaneous tissue (Figure  6 b). To determine 
whether the microneedle-implanted particles persist in the 
skin, we performed similar analyses of treated skin 10 days after 
microneedle administration. DiD-loaded microparticles were 
still found several hundred micrometers deep within the skin at 
this timepoint by histology (Figure  6 c). However, tissue sections 
collected after 10 days consistently showed the loss of AF488 
signal within the tissue at the sites of microneedle insertion, © 2013 WILEY-VCH Verlag GmAdv. Funct. Mater. 2013, 23, 161–172indicating the clearance of soluble PAA-loaded cargo over this 
time period. 
 Given the ability of composite microneedles to implant cuta-
neous microparticle deposits that were retained at the treat-
ment site for long periods of time, we hypothesized that these 
microneedles might serve as an effective platform for sustained 
delivery of PLGA-loaded drugs, while also providing an oppor-
tunity to rapidly deliver bolus doses of additional cargos encap-
sulated in the PAA matrix. To determine the time course for 
cargo delivery following microneedle application, we performed 
composite microneedle treatments on the dorsal ear skin of 
C57Bl/6 mice as before, to deliver DiD-loaded PLGA micro-
particles together with PAA-loaded AF488. Tissue retention 
and clearance of these fl uorescent model drug cargos was then 
monitored using whole animal fl uorescent imaging. Results 
of this analysis showed that PAA-loaded AF488 was rapidly 
cleared from the site of application within 1 day, while DiD-
fl uorescent signal was retained within the ear skin for greater 
than 20 days following delivery (Figure  6 d,e). These results are 
consistent with the previous confocal and histological analyses 
already discussed, and together support the hypothesized mech-
anism of microneedle insertion, followed by PAA dissolution, 
and needle disintegration to form long-lived cutaneous PLGA 
particle depots for sustained release over time. Similar whole 
animal imaging results obtained following delivery of bulk 
PLGA implants suggest an equivalent mechanism for com-
posite microneedles of this variation (Figure S3, Supporting 
Information). 
 Nanoparticles and microparticles deposited in skin are known 
to be phagocytosed over time and transported to draining lymph 
nodes by antigen presenting cells. [ 35– 37 ] This transport process 
could affect the biodistribution of particle-released drugs and is 
an important factor in particle-based vaccines. To assess transit 
of particles from microneedle insertion sites to draining lymph 
nodes over time, confocal imaging of histologically sectioned 
draining lymph nodes was performed to detect the presence 
of microneedle-delivered cargos 10 days after treatment. These 
analyses clearly showed the presence of both AF488 (our model 
water-soluble PAA-encapsulated drug) and microparticle-loaded 
DiD within the subcapsular sinus of sectioned lymph nodes, 
suggesting these materials were able to drain through the lym-
phatics following release at the cutaneous depot site (Figure  6 f). 
Further, intact microparticles were observed by high magnifi ca-
tion imaging within the cortical regions of the lymph nodes, 
indicating traffi cking of particles by cells from the implantation 
site. No fl uorescent signal was observed in lymph nodes from 
untreated animals (data not shown). Together these results 
support the idea that cutaneously delivered soluble materials 
as well as microparticles themselves are traffi cked to draining 
lymph nodes. 
 2.6. Composite Microneedle Subunit Vaccine Delivery 
 As a fi nal test of the ability of composite microneedles to pro-
vide effective therapeutic delivery in vivo , we fabricated arrays 
for the transcutaneous delivery of a subunit vaccine formula-
tion. We synthesized PLGA microparticles encapsulating Cy3-
labeled poly(I:C) (Cy3-poly(I:C)), a synthetic double stranded 167wileyonlinelibrary.combH & Co. KGaA, Weinheim
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 Figure  6 .  Composite DiD-loaded PLGA microparticle/AF488-loaded PAA microneedles were applied to the fl ank or dorsal ear skin of C57Bl/6 mice 
for 5 min, followed by histological, confocal microscope, and whole-animal fl uorescence analysis at 1–18 days post treatment. a) Histological sec-
tion of treated skin 24 h following microneedle array application. Microparticles are shown implanted together with AF488-loaded PAA at a single 
microneedle penetration site (scale bar 200  μ m). b) Parallel  x - y / x - z / y - z confocal reconstruction of the treatment site at 24 h post application shows 
DiD-loaded microparticle depots persisting at the penetration sites (left, scale bar 100  μ m). High magnifi cation imaging at a single penetration site 
shows microparticle dispersion within the cutaneous tissue (right, scale bar 20  μ m). c) Histological section of skin 10 days following microneedle 
application (scale bar 200  μ m). d) Whole animal fl uorescence imaging of mice 1, 5, and 18 days after microneedle array application. Fluorescence 
signal from released AF488 and DiD-PLGA microparticles is shown. e) Quantifi cation of relative AF488 and DiD whole-animal fl uorescence signal 
detected at microneedle application sites. f) Histological section of the draining inguinal lymph node 10 days after microneedle application showing 
persistence of DiD PLGA-loaded cargos in the subcapsular sinus (left, scale bar 100  μ m), as well as cell-traffi cked PLGA particles in the cortical regions 
(arrows in inset at right, scale bar 10  μ m). RNA mimic of viral RNA, as a molecular adjuvant. [ 38 ] Micro-
needles composed of poly(I:C)-loaded PLGA particles and 
fl uorescently labeled ovalbumin (AF647-OVA, model antigen) 
embedded in a supporting PAA matrix were fabricated fol-
lowing the approach of Figure  1 . Characterization of the 
resulting microneedles using confocal imaging showed restric-
tion of the Cy3-poly(I:C) microparticles in the microneedle tips, 
with fl uorescent signal from AF647-OVA throughout the micro-
needle length ( Figure  7 a). Upon application of these vaccine-
loaded composite microneedles to the dorsal ear skin of mice, 
we observed successful deposition of both antigen and adju-
vant at the application site using whole-animal fl uorescence 68 wileyonlinelibrary.com © 2013 WILEY-VCH Verlag Gimaging (Figure  7 b), consistent with our previous results using 
model drug cargos. 
 To test the effi cacy of these dissolving composite micronee-
dles for vaccination compared to traditional vaccine administra-
tion, mice were immunized on day 0 and boosted on day 35 with 
15  μ g ovalbumin and 50 ng PLGA-encapsulated poly(I:C) admin-
istered either intramuscularly (IM) in the quadriceps, intrader-
mally (ID) in the dorsal ear skin, or by microneedle application 
(MN) for 5 min, also at the dorsal ear site. We then monitored 
the induction of OVA-specifi c cellular immunity through the 
detection of OVA-reactive CD8  +  T cells using fl ow cytometry. 
Two weeks following the fi rst immunization we observed mbH & Co. KGaA, Weinheim Adv. Funct. Mater. 2013, 23, 161–172
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 Figure  7 .  a,b) Composite microneedles were fabricated, comprised of Cy3-labeled poly(I:C)-loaded PLGA microparticles surrounded by PAA with 
entrapped AF647-ovalbumin. a) Confocal microscopy image of composite microneedles (right, scale bar 200  μ m). b) Whole animal fl uorescence 
imaging of mice treated with microneedles after 1 day. c–f) Groups of C57Bl/6 mice ( n  = 4) were vaccinated with 15  μ g ovalbumin and 50 ng poly(I:C) 
intramuscularly (IM), intradermally in the dorsal ear skin (ID), or administered transcutaneously to the ear via microneedles (MN), with the poly(I:C) 
entrapped in PLGA microparticles and ovalbumin entrapped in the PAA phase. Mice were primed on day 0 and boosted on day 35 with identical 
formulations. c) Frequency of SIINFEKL-specifi c T cells in peripheral blood assessed by fl ow cytometry analysis of peptide-MHC tetramer  +  CD8  +  T 
cells. Shown are representative cytometry plots from individual mice and d) mean tetramer  +  frequencies from day 49. e) Analysis of T-cell effector/
central memory phenotypes in peripheral blood by CD44/CD62L staining on tetramer  +  cells from peripheral blood. Shown are mean percentages of 
tetramer  +  CD44  +  CD62L  +  among CD8  +  T cells at day 63. f) Frequency of tetramer  +  CD8  +  T cells in peripheral blood producing IFN- γ and TNF- α following 
SIINFEKL restimulation assessed by fl ow cytometry. Shown are representative cytometry plots from individual mice and mean cytokine  +  frequencies 
for day 56. g) Enzyme-linked-immunosorbent assay analysis of total ovalbumin-specifi c IgG in sera at day 63. expansion of antigen-specifi c CD8  +  T cells to  ≈ 2% of the total 
CD8  +  population in all treatment groups, suggesting that 
microneedle delivery provided similar initial immunogenicity 
compared with traditional parenteral immunization strategies 
(Figure S4a, Supporting Information). Upon contraction of the © 2013 WILEY-VCH Verlag GAdv. Funct. Mater. 2013, 23, 161–172antigen-specifi c T cell population two weeks later, we measured 
the frequency of antigen-specifi c CD44  +  CD62L  +  cells, central 
memory T cells that have been correlated with long-lived effec-
tive protection against re-exposure to pathogens. [ 39 ] On day 28, 
we observed that microneedle immunization generated central 169wileyonlinelibrary.commbH & Co. KGaA, Weinheim
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either intramuscular or intradermal vaccination, with greater 
than 30% of OVA-specifi c memory T-cells expressing CD44 and 
CD62L (Figure S4b, Supporting Information). These trends 
were similarly observed after the booster immunization, with 
antigen-specifi c T-cells reaching  ≈ 5% of the total CD8  +  popu-
lation in mice receiving ID or MN dosing (Figure  7 c,d). Sim-
ilar to the pre-boost response, elevated frequencies of central 
memory CD8  +  T cells were observed in microneedle vaccinated 
mice after contraction of the response on day 63, compared to 
both control IM and ID injected vaccine groups (Figure  7 e). 
We also evaluated the functional capacity of the vaccine-elicited 
T-cell response through detection of cytokine production fol-
lowing re-stimulation of peripheral blood mononuclear cells 
with SIINFEKL peptide (the immunodominant peptide from 
OVA in C57Bl/6 mice). These analyses indicated enhanced 
cytokine production by T-cells elicited by microneedle vaccina-
tion for antigen-dependent production of both IFN- γ and TNF-
 α , key cytokines for combating viral infection (Figure  7 f). Fur-
thermore, microneedle delivery generated a higher frequency 
of multi-functional CD8  +  T cells able to secrete both IFN- γ and 
TNF- α upon peptide stimulation. Together these results indi-
cate the ability of microneedle immunization with slow-released 
adjuvant to elicit phenotypically and functionally superior cel-
lular immunity compared to traditional vaccine administration. 
Finally, we measured the level of ovalbumin-specifi c IgG in the 
sera of immunized animals to compare the capacity for gen-
erating humoral immunity. Here we observed the presence of 
similarly high levels of anti-ovalbumin IgG in all immunized 
animals on day 63, suggesting that composite microneedle 
delivery can also generate antibody responses comparable to 
traditional immunization strategies (Figure  7 g). Notably, the 
microneedles used in these vaccination studies were fabri-
cated and stored dry at 25  ° C for between 4 and 8 weeks before 
administration for both the prime and boost immunizations, 
indicating the potential for long-term maintenance of vaccine 
potency without the need for cold storage, a pressing need for 
the effective distribution of vaccines to remote areas of the 
developing world. Taken as a whole, these results demonstrate 
the strength of our approach for rapid transcutaneous multi-
component delivery using composite PLGA-PAA microneedles. 
 3. Conclusions 
 Here we have demonstrated an approach for modular cargo 
encapsulation into composite dissolving microneedles for rapid 
delivery of PLGA microparticles or solid tips to form long-lived 
cutaneous depots promoting controlled and sustained release 
over several weeks. The combination of PLGA-formulated drug 
with a rapidly water-soluble PAA supporting matrix (in the case 
of microparticles) or pedestal (in the case of solid PLGA tips) 
provides the combined ability to rapidly and simply deliver the 
PLGA payload upon application to skin for only 5 min and to 
maintain drug release from implanted PLGA depots long after 
removal of the microneedle backing. Additionally, this com-
posite microneedle architecture provides substantial fl exibility 
in loading of single or multiple diverse cargos either into PLGA 
through standard double emulsion particle synthesis, or into the wileyonlinelibrary.com © 2013 WILEY-VCH Verlag Gsupporting PAA matrix through simple co-dissolution during 
fabrication. The composite structure also allows for simple 
tuning of extended cargo release kinetics through selection of 
PLGA copolymer ratio and molecular weight or bolus delivery 
upon needle disintegration through encapsulation in the PAA 
matrix. We have demonstrated the utility of these microneedle 
designs for the systemic dispersion of drugs released upon 
skin insertion or upon release from implanted PLGA over 
time. Finally, we have shown the successful application of this 
materials platform for encapsulation and delivery of a protein 
vaccine formulation generating potent humoral and cellular 
immunity matching or exceeding that resulting from traditional 
needle-based vaccine administration, even after storage for sev-
eral weeks at room temperature. Together these results suggest 
that PLGA-PAA composite microneedles are an effective plat-
form for straightforward and robust transcutaneous drug and 
vaccine delivery. Aside from applications in vaccination, the 
fl exibility and modularity of this approach suggests its potential 
to serve as a platform for generalized therapeutics delivery pro-
viding both rapid and convenient administration as well as the 
potential for controlled and sustained systemic delivery. 
 4. Experimental Section 
 PLGA Microparticle Synthesis: Polyvinyl alcohol (PVA)-stabilized PLGA 
microparticles were prepared by a single/double emulsion/solvent 
evaporation approach. Briefl y, 80 mg PLGA (50:50 lactide:glycolide 
ratio, IV 0.35 dL/g, Lakeshore Biomaterials or Resomer RG 755 S, IV 
0.70 dL/g) was dissolved in 5 mL dichloromethane. The PLGA solution 
was then added to 40 ml 0.5% PVA (MW 150,000 Da, MP Biomedicals) 
while homogenizing at 12,000rpm using a T-25 Digital Homogenizer 
(IKA). Homogenization was performed for 3 min following PLGA 
addition, and solvent was subsequently removed by stirring overnight. 
For fl uorescently labeled particles 160 ug 1,1 ′ -dilinoleyl-3,3,3 ′ ,3 ′ -
tetramethylindocarbocyanine (DiI) or 1,1 ′ -dioctadecyl-3,3,3 ′ ,3 ′ -
tetramethylindodicarbocyanine (DiD, Invitrogen) were codissolved 
with PLGA. For poly(I:C) loaded particles, 3mg Cy3-labeled poly(I:C) 
(Invivogen, labeled using Mirus LabelIT, according to the manufacturer’s 
instructions) was dissolved in distilled water and added to the polymer-
containing organic phase while sonicating at 12W with a Microson XL 
probe tip (Microson). After sonication for 30 s the resulting emulsion 
was added to the PVA solution and homogenized as before. The resulting 
particles were collected by centrifugation, washed, and resuspended in 
distilled water before lyophilization and storage under dessication at 
4  ° C until use. Particle size and zeta potential was determined using a 
BIC 90 + light scattering instrument (Brookhaven Instruments Corp). 
 Microneedle Fabrication: Microneedles encapsulating free PLGA 
microparticles or bulk PLGA implants were fabricated from PDMS molds 
(Sylgard 184, Dow Corning) machined using laser ablation (Clark-MXR, 
CPA-2010 micromachining system) to create patterns of micron-scale 
surface-cavities. First, PLGA microparticles were deposited into PDMS 
molds through addition of aqueous particle suspensions to the mold 
surface. Following PLGA microparticle addition (0.2–3.0 mg/array), 
molds were centrifuged for 20 min at rcf  ≈ 2 to compact particles into 
mold cavities. Following removal of residual material from the mold 
surface, molds were dried at 25  ° C. For microneedles encapsulating 
free microparticles, addition of 35% poly(acrylic acid) (PAA, 250kDa) to 
the mold surface was followed by centrifugation (20 min, rcf  ≈ 2) and 
drying at 25  ° C (48 h on the benchtop, followed by 2–14 days under 
dessication), before removal. Microneedles encapsulating multiple 
distinct particle populations were fabricated similarly through addition 
of mixed particle suspensions. For microneedles encapsulating bulk 
PLGA implants, PDMS molds encapsulating free microparticles were mbH & Co. KGaA, Weinheim Adv. Funct. Mater. 2013, 23, 161–172
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heated under vacuum (–25 in. Hg) at 145  ° C for 40 min, and then 
cooled at –20  ° C before addition of 35% PAA, centrifugation, and drying 
as previously described. For microneedles encapsulating layered PLGA 
implants, sequential microparticle deposition, drying, and melting was 
performed as previously described. All microneedles were stored under 
dessication at 25  ° C until use. Microneedle arrays were characterized by 
scanning electron microscopy (SEM) using a JEOL 6700F FEG-SEM and 
confocal microscopy using a Zeiss LSM 510. 
 Characterization of Microparticle and Implant Delivery : Microparticle 
and bulk implant release was characterized in vitro through brief ( < 30 s) 
exposure of fabricated arrays to PBS. Microparticles and bulk implants 
were then collected through centrifugation and washed in PBS before 
application of aqueous suspensions to glass coverslips. After drying, 
microparticles and implants were imaged by confocal microscopy. 
Similar delivery was measured in vivo following array application to the 
skin of mice. Animals were cared for in the USDA-inspected MIT Animal 
Facility under federal, state, local, and NIH guidelines for animal care. 
Microneedle application experiments were performed on anesthetized 
C57BL/6 mice (Jackson Laboratories) at the fl ank or dorsal ear skin. Skin 
was rinsed briefl y with PBS and dried before application of microneedle 
arrays by gentle pressure. Following application mice were euthanized 
at subsequent time points and the application site and draining lymph 
nodes were dissected. Excised skin was stained with trypan blue before 
imaging for needle penetration. In separate experiments treated skin 
and applied microneedle arrays were imaged by confocal microscopy 
to assess transcutaneous delivery of encapsulated microparticles and 
bulk implants. In some cases, treated skin was excised and fi xed in 
3.7% formaldehyde for 18 h, then incubated in 30% sucrose/PBS for 
2 h before embedding in optimal cutting temperature (OCT) medium 
(Tissue-Tek) for histological sectioning on a cryotome. Lymph nodes 
were similarly embedded in OCT and sectioned. Histological sections 
were then imaged using confocal microscopy. 
 In Vivo Imaging : Live whole animal imaging was performed using a 
Xenogen IVIS Spectrum (Caliper Life Sciences) on anesthetized mice. 
Fluorescence data was processed using region of interest (ROI) analysis 
with background subtraction and internal control ROI comparison to 
untreated skin using the Living Image 4.0 software package (Caliper). 
 Immunizations : All animal studies were approved by the MIT IUCAC 
and animals were cared for in the USDA-inspected MIT Animal Facility 
under federal, state, local, and NIH guidelines for animal care. Groups of 
4 C57Bl/6 mice were immunized on days 0 and 35 with 15  μ g ovalbumin 
and 50 ng poly(I:C) by intramuscular injection (15  μ L in the quadriceps) 
intradermal injection (15  μ L in the dorsal caudal ear skin) or by 
microneedle array (5 min application). Frequencies of OVA-specifi c CD8  +  
T-cells and their phenotypes elicited by immunization were determined 
by fl ow cytometry analysis of peripheral blood mononuclear cells at 
selected time points following staining with DAPI (to discriminate live/
dead cells), anti-CD8 α , anti-CD44, anti-CD62L (BD Biosciences), and 
phycoerythrin-conjugated SIINFEKL/H-2K b peptide-MHC tetramers 
(Beckman Coulter). To assess the functionality of primed CD8  +  T-cells 
peripheral blood mononuclear cells were stimulated ex vivo with 10 ug/
mL OVA-peptide SIINFEKL for 6 h with Brefeldin-A (Invitrogen), fi xed, 
permeabilized, stained with anti-IFN γ , anti-TNF α , and anti-CD8 α (BD 
Biosciences), and analyzed by fl ow cytometry. Anti-Ovalbumin IgG 
titers, defi ned as the dilution of sera at which 450 nm OD reading was 
0.25, were determined by ELISA analysis of sera from immunized mice. 
Animals were cared for following NIH, state, and local guidelines. 
 Supporting Information 
 Supporting Information is available from the Wiley Online Library or 
from the author. 
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